E3330

Contact us
TargetMol
Product Code: TAR-T6823
Supplier: TargetMol
CodeSizePrice
TAR-T6823-1mg1mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-2mg2mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-1mL1 mL * 10 mM (in DMSO)£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-5mg5mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-10mg10mg£212.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-25mg25mg£327.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-50mg50mg£493.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-100mg100mg£683.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-200mg200mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6823-500mg500mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1
❮❯

Documents

Further Information

Bioactivity:
E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.
CAS:
136164-66-4
Formula:
C21H30O6
Molecular Weight:
378.465
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
CCCCCCCCCC(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O
Target:
DNA/RNA Synthesis

References

Zou GM, et al. Blood. 2007, 109(5), 1917-1922. Cesaratto L, et al. PLoS One. 2013, 8(8), e70909. Nagakawa J, et al. J Pharmacol Exp Ther. 1993, 264(1), 496-500. Zou GM, et al. Mol Cancer Ther. 2008, 7(7), 22012-2021. Guerreiro PS, et al. The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Chem Biol Drug Des. 2017 Oct;90(4):561-571. Nagakawa J, et al. J Pharmacol Exp Ther. 1992, 262(1), 145-150.